Home>>Analytical Standards>> Certified Reference Materials>>Naloxone-d5

Naloxone-d5 Sale

(Synonyms: 纳洛酮D5) 目录号 : GC47743

A Certified Reference Material

Naloxone-d5 Chemical Structure

Cas No.:1261079-38-2

规格 价格 库存 购买数量
1 mg
¥5,106.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Naloxone-d5 is an analytical reference material intended for use as an internal standard for the quantification of naloxone by GC- or LC-MS. Naloxone is categorized as an opioid antagonist.1 Formulations containing naloxone have been used as antidotes for opioid overdose and the prevention of overdose.2,3 They have also been used in combination with buprenorphine in the treatment of opiate addiction and in pain management.4,5 This product is intended for research and forensic applications.

1.Le Bourdonnec, B., Barker, W.M., Belanger, S., et al.Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as μ opioid receptor antagonists with improved opioid receptor selectivity profilesBioorg. Med. Chem. Lett.18(6)2006-2012(2008) 2.Boyer, E.W.Management of opioid analgesic overdoseN. Engl. J. Med.367(2)146-155(2012) 3.Bowman, S., Eiserman, J., Beletsky, L., et al.Reducing the health consequences of opioid addiction in primary careAm. J. Med.126(7)565-571(2013) 4.Bart, G.Maintenance medication for opiate addiction: The foundation of recoveryJ. Addict. Dis.31(3)207-225(2012) 5.Chen, K.Y., Chen, L., and Mao, J.Buprenorphine-naloxone therapy in pain managementAnesthesiology120(5)1262-1274(2014)

Chemical Properties

Cas No. 1261079-38-2 SDF
别名 纳洛酮D5
Canonical SMILES O[C@]12[C@]3(CCN(C([2H])(/C([2H])=C([2H])/[2H])[2H])[C@@H]2C4)[C@](OC5=C3C4=CC=C5O)([H])C(CC1)=O
分子式 C19H16D5NO4 分子量 332.4
溶解度 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 3.0084 mL 15.0421 mL 30.0842 mL
5 mM 0.6017 mL 3.0084 mL 6.0168 mL
10 mM 0.3008 mL 1.5042 mL 3.0084 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Simultaneous determination of morphine-6-d-glucuronide, morphine-3-d-glucuronide and morphine in human plasma and urine by ultra-performance liquid chromatography-tandem mass spectrometry: Application to M6G injection pharmacokinetic study

Biomed Chromatogr 2018 Feb;32(2).PMID:28833311DOI:10.1002/bmc.4066

A robust ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the determination of morphine-6-d-glucuronide (M6G), morphine-3-d-glucuronide (M3G) and morphine (MOR) in human plasma and urine has been developed and validated. The analytes of interest were extracted from plasma by protein precipitation. The urine sample was prepared by dilution. Both plasma and urine samples were chromatographed on an Acquity UPLC HSS T3 column using gradient elution. Detection was performed on a Xevo TQ-S tandem mass spectrometer in multiple reaction monitoring mode using positive electrospray ionization. Matrix interferences were not observed at the retention time of the analytes and internal standard, Naloxone-d5. The lower limits of quantitation of plasma and urine were 2/0.5/0.5 and 20/4/2 ng/mL for M6G/M3G/MOR, respectively. Calibration curves were linear over the concentration ranges of 2-2000/0.5-500/0.5-500 and 20-20,000/4-4000/2-2000 ng/mL for M6G/M3G/MOR in plasma and urine samples, respectively. The precision was <7.14% and the accuracy was within 85-115%. Furthermore, stability of the analytes at various conditions, dilution integrity, extraction recovery and matrix effect were assessed. Finally, this quantitative method was successfully applied to the pharmacokinetic study of M6G injection in Chinese noncancer pain patients.